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Biscoumarin analogs were synthesized by the reaction between two equivalent of 4-hydroxycoumarin and
one equivalent of aryl aldehydes induced by visible light [22 W compact ﬂuorescent lamp (CFL) bulb]. This
new method is simple, cost-effective, and furnished excellent yields with broad substrate generality in short
reaction time.
J. Heterocyclic Chem., 55, 1375 (2018).
INTRODUCTION
Because of environmental and societal interests, there has
been a great demand for the development of the simple and
environmental benign synthetic methods that minimizes the
use of toxic reagents, catalysts, acids, alkali, and hazardous
solvents [1]. The pursuit of greener and facile synthesis to
prepare various organic compounds continues to be
challenging. Among numerous green methods, the use of
visible light [compact ﬂuorescent lamp (CFL) bulb] has
received much attention.
Biscoumarins are an important class that often display
diverse biological activities [2,3] such as antitumor [4],
anti-inﬂammatory [5], antioxidant [6], and cytotoxicity
[7]. These compounds are widely used as ligands [8],
reducing and stabilizing agent [9], dyes [10], etc. Up to
date, many biscoumarin analogs have been discovered
from the natural sources [11] including Dicoumarol
(Melilotus alba), Gerberinol (Gerbera lanuginose),
Ismailin (Diospyros ismaili), and Bisosthenon (Citrus
funadokoao) (Fig. 1).
Many synthetic approaches have been reported
for the synthesis of biscoumarins [12–15]. The
most important protocols are from (i) benzylic alcohols
and 4-hydroxycoumarin [16], (ii) 1,2-diols and
4-hydroxycoumarin [17], and (iii) benzaldehydes and
4-hydroxycoumarin [18]. The last method is of particular
interest, and much development has been progressed.
In the last decades, use of various catalytic conditions
has been established for the preparation of biscoumarins
from 4-hydroxycoumarin and aryl aldehydes such as
molecular iodine [19], Zn(proline)2 [20], tetramethyl
guanidium [21], phosphotungstic acid [22], nano silica
chloride [23], propane-1,2,3-triyltris(hydrogen sulfate)
[24], choline hydroxide [25], poly(4-vinylpyridine)-
supported ionic liquids [26], ruthenium(III) chloride
hydrate [27], sulfated titania [28], methane sulfonic acid
[29], sodium dodecyl sulfate [30], ruthenium [31], nano
TiO2@KSF [32], silica-bonded n-propyl diethylene
triamine sulfamic acid [33], and W-doped ZnO
nanocomposite [34]. However, these methods suffer from
the limitations such as use of expensive, toxic, greater
loading of catalysts, incomplete conversion, and lower
yields. Prompted by the previous points and our
continuous efforts for preparing heterocyclic derivatives
[35–37], we envisioned the catalyst-free synthesis of
biscoumarin derivatives using visible light (CFL bulb)
system at ambient temperature.
To date, no report has described the synthesis of
biscoumarins under CFL light irradiation. CFL light
intensity is harmless and an easily available energy
source. CFL light intensity proved to be a very useful
source in the synthesis of unsymmetrical diynes [38],
cyclocondensation of pyrrole [39], photocatalytic
generation of H2 [40], carboxylation [41], synthesis of
1,2-diketones [42], triﬂuromethylated alkenes [43], diaryl
disulﬁdes [44], oxysulfonylation of alkenes [45],
3,4-dithiophenes [46], benzothiazoles [47], photochromic
molecules [48], iron(III)-based metal organic frame works
[49], and photocatalyst [50].
Therefore, the present synthesis of biscoumarins is
novel, highly efﬁcient, cost-effective, environmentally
sustainable, and compatible for catalytic, biomedical, and
industrial applications.
© 2018 Wiley Periodicals, Inc.
RESULTS AND DISCUSSION
In order to establish the optimal conditions for the
synthesis of biscoumarins, 4-hydroxycoumarin (2) and
benzaldehyde (1g) were chosen as a model substrate and
allowed to react in the presence of visible light (20 W,
CFL) intensity in DMF at room temperature for 4 h
(Scheme 1). The presence of visible light intensity was
crucial because, in its absence, the reaction did not
proceed. The initial examination, to our delight, showed
that CFL light intensity can catalyze the model reaction
to afford the (3g) in 46 % yield.
A survey on intensities of light and solvent suggests that
ethanol at 22 W is optimum because its reaction time and
yields are better than those of others (Table 1). When the
temperature was increased from room temperature to
78°C (reﬂux), the time and yield of the reaction was not
improved. Therefore, room temperature, ethanol solvent,
and 22 W CFL light intensity were selected as the
optimal reaction condition for further experiments. When
taking 2:1 molar ratio of 4-hydroxycoumarin (2) and
benzaldehyde (1g), which are condensed under visible
light intensity, the target compound (3g) was obtained in
95% yield.
Encouraged by the remarkable optimization results, we
explored the generality and scope of the protocol by
reacting 4-hydroxycoumarin with structurally diverse
aldehydes (Table 2) under optimized conditions. The
reaction effectively proceeded with both electron
donating and electron withdrawing precursors.
Interestingly, hetero aromatic aldehydes such as indole
and thiophene were found to be equally efﬁcient at
yielding the expected products in excellent yields.
In accordance with previous literature reports [50–54], a
plausible radical mechanism is proposed (Scheme 2). It is
proposed that the aldehydes undergo Norrish-type
Scheme 1. Synthesis of biscoumarin (3g) under visible light. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
Table 1
Optimization of solvent and visible light intensity for the synthesis of (3g).
Entry Solvent Visible light intensity (W) Time (h) Yield (%)
1 CH2Cl2 20 5.5 41
2 Dioxane 20 6.5 78
3 Acetonitrile 20 4 67
4 Toluene 20 4.5 70
5 THF 20 5 72
6 Methanol 20 3.5 82
7 DMF 20 4.0 46
8 DMSO 20 5.5 52
9 Ethanol 20 2.3 88
10 Ethanol 22 2 95
11 Ethanol 15 3.1 77
12 Ethanol 8 4.2 69
13 Ethanol 32 2 95
Figure 1. Some naturally occurring biscoumarins.
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Table 2
Visible light-induced synthesis of biscoumarin analogs under optimized condition.
Entry Ar Product Time (h) Yield (%) Obs.Mp (°C) Lit.Mp (°C)
1 3a 2 92 144–146 –
2 3b 2.2 91 199–201 –
3 3c 2.7 91 255–257 –
4 3d 2.2 90 212–214 –
5 3e 1.9 88 255–257 –
6 3f 2.8 87 245–247 264–266(27)
7 3g 2.3 95 228–230 230–231(12)
8 3h 2.5 96 234–236 232–233(12)
9 3i 2.6 89 250–252 251–252(12)
10 3j 2.3 92 259–261 259–260(12)
11 3k 2.5 96 265–267 266–268(12)
12 3l 2.6 89 215–217 214–216(12)
13 3m 2.5 91 242–244 241–243(12)
14 3n 2.8 90 264–266 263–265(12)
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cleavage and phenolic hydrogen of the 4-hydroxycoumarin
breaks symmetrically to form the radical. These radicals
further react to form the intermediates I, II, and III and
ﬁnally gives the stable biscoumarin analogs. To verify
whether the reaction proceeds through radical pathway or
ionic pathway, the same model reaction was performed in
the presence of hydroquinone, which is a radical inhibitor
[55]. Only a trace amount of product (3g) was produced.
This experiment clearly exhibited that the reaction
proceeded via a radical pathway.
CONCLUSION
Eventually, we can conclude that visible light (CFL
bulb, 22 W) can induce reaction between two equivalent
of 4-hydroxy coumarin and one equivalent of aryl
aldehydes to produce biscoumarin derivatives. The
excellent yield, broad substrate proﬁle, short reaction
time, and catalyst free are the merits of this protocol.
GENERAL INFORMATION
The melting points were determined using electric
melting point apparatus and are uncorrected. NMR
spectra were recorded on a Jeol spectrometer (400 MHz
for H1-NMR and 100 MHz for C13-NMR) using TMS as
an internal standard in CDCl3. Chemical shifts (δ) are
measured in ppm. The progress of the reaction and purity
of the compounds were checked by TLC. The elemental
analyses were performed on Elemental Vario Micro Cube
CHN Rapid Analyzer. Philips CFL bulbs are used as a
visible light source.
General experimental procedure for the synthesis of
biscoumarin derivatives (3a–n). A mixture of
arylaldehydes (1 mmol), 4-hydroxycoumarin (2 mmol),
and ethanol (10 mL) was taken in a 100-mL beaker. A
glowing CFL bulb (22 W) was placed inside the
beaker but just above (2-cm height) the reaction
mixture. The reaction mixture was stirred at RT for the
time shown in Table 2. The progress of the reaction
was monitored by TLC (Eluent: EtOAc and n-hexane).
The evaporation of solvent in vacuo afforded the crude
product, which was recrystallized from ethanol to
obtain biscoumarins.
SPECTRAL DETAILS
4-Hydroxy-3-((4-hydroxy-2-oxo-2H-chromen-3-yl)(2-
phenyl-1H-indol-3-yl)methyl)-2H-chromen-2-one (3a). A
purple solid; 1H NMR (CDCl3 400 MHz): δ 5.82 (s, 1H,
CH), 7.08–7.67 (m, 17H, Ar-H), 8.40 (s, 1H, OH), 8.42
Scheme 2. Plausible free radical mechanism for the synthesis of biscoumarins. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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(s, 1H, OH), 8.87 (s, 1H, NH) ppm. 13C NMR (CDCl3
100 MHz): δ 36.0, 110.8, 111.0, 116.7, 122.3, 123.3,
123.5, 124.1, 124.5, 125.1, 129.0, 129.2, 129.5, 130.1,
132.6, 138.2, 144.0, 144.2, 144.5, 144.7, 155.7, 155.9,
165.7, 165.9 ppm. HRMS: [M + H] = m/z 528.6214;
Anal. Calcd for C33H21NO6: C, 75.13; H, 4.01; N, 2.66;
found: C, 75.10; H, 4.00; N, 2.63%.
3-((5-Bromothiophen-2-yl)(4-hydroxy-2-oxo-2H-chromen-
3-yl)methyl)-4-hydroxy-2H-chromen-2-one (3b). A light
yellow solid; 1H NMR (CDCl3 400 MHz): δ 6.09 (s, 1H,
CH) 6.60–7.64 (m, 10H, Ar-H), 8.02 (s, 1H, OH), 8.04
(s, 1H, OH) ppm. 13C NMR (CDCl3 100 MHz): δ 51.7,
110.7, 116.7, 124.4, 125.0, 125.7, 141.5, 147.0, 147.4,
148.2, 159.3, 159.6, 160.9, 164.9 ppm. HRMS: [M] = m/
z 497.3352; Anal. Calcd for C23H13BrO6S; C, 55.55; H,
2.63; found: C, 55.53; H, 2.62%.
3-((4-Fluoro-2-chlorophenyl)(4-hydroxy-2-oxo-2H-
chromen-3-yl)methyl)-4-hydroxy-2H-chromen-2-one (3c).
A white solid; 1H NMR (CDCl3 400 MHz): δ 6.02 (s,
1H, CH) 6.82–7.64 (m, 11H, Ar-H), 7.99 (s, 1H, OH),
8.05 (s, 1H, OH) ppm. 13C NMR (CDCl3 100 MHz):
δ 55.2, 114.0, 116.6, 124.3, 124.8, 126.7, 127.6, 132.7,
146.9, 147.6, 152.2, 158.4, 163.9, 164.2 ppm. HRMS:
[M + H] = m/z 464.1414; Anal. Calcd for C25H14ClFO6:
C, 64.60; H, 3.04; found: C, 64.59; H, 3.03%.
3-((4-Ethoxyphenyl)(4-hydroxy-2-oxo-2H-chromen-3-yl)
methyl)-4-hydroxy-2H-chromen-2-one (3d). A white solid;
1H NMR (CDCl3 400 MHz): δ 1.37 (t, 3H, CH3) 3.98 (q,
2H, CH2), 6.03 (s, 1H, CH), 6.82–7.63 (m, 12H, Ar-H),
8.00 (s, 1H, OH), 8.04 (s, 1H, OH) ppm. 13C NMR
(CDCl3 100 MHz): δ 19.0, 38.0, 63.4, 114.5, 116.6,
124.3, 124.8, 126.7, 127.5, 132.7, 139.9, 140.2, 140.5,
157.8, 163.9, 164.1 ppm. HRMS: [M + H] = m/z
457.0342; Anal. Calcd for C27H20O7: C, 71.05; H, 4.42;
found: C, 71.03; H, 4.40%.
4-Hydroxy-3-((4-hydroxy-2-oxo-2H-chromen-3-yl)(2,3-
dimethoxyphenyl)methyl)-2H-chromen-2-one (3e). Awhite
solid; 1H NMR (CDCl3 400 MHz): δ 3.72 (s, 3H, OCH3),
3.85 (s, 3H, OCH3), 6.17 (s, 1H, CH), 6.86–7.61 (m, 11H,
Ar -H), 8.00 (s, 1H, OH), 8.01 (s, 1H, OH) ppm. 13C
NMR (CDCl3 100 MHz): δ 33.4, 55.7, 59.9, 110.0, 110.2,
110.3, 110.7, 111.0, 111.7, 116.5, 116.8, 120.1, 123.5,
124.3, 124.7, 129.3, 132.4, 139.3, 139.3, 143.2, 143.4,
144.2, 147.2, 152.1, 159.1, 160.9, 163.8 ppm. HRMS:
[M + H] = m/z 473.1945; Anal. Calcd for C27H20O8: C,
68.64; H, 4.27; found: C, 68.60; H, 4.24%.
4-Hydroxy-3-((4-hydroxy-2-oxo-2H-chromen-3-yl)(3,4-
dimethoxyphenyl)methyl)-2H-chromen-2-one (3f). A white
solid; 1H NMR (CDCl3 400 MHz): δ 3.72 (s, 3H, OCH3),
3.85 (s, 3H, OCH3), 6.06 (s, 1H, CH) 6.70–7.63 (m, 11H,
Ar-H), 8.00 (s, 1H, OH), 8.05 (s, 1H, OH) ppm. 13C NMR
(CDCl3 100 MHz): δ 35.2, 55.7, 56.0, 110.3, 111.2, 116.6,
118.9, 124.3, 124.8, 127.5, 132.8, 139.2, 139.5, 139.7,
148.0, 149.1, 161.8, 162.1 ppm. HRMS: [M + H] = m/z
473.6214; Anal. Calcd for C27H20O8: C, 68.64; H, 4.27;
found: C, 68.60; H, 4.24%.
4-Hydroxy-3-((4-hydroxy-2-oxo-2H-chromen-3-yl)(phenyl)
methyl)-2H-chromen-2-one (3g). A white solid; 1H NMR
(CDCl3 400 MHz): δ 6.09 (s, 1H, CH), 7.20–7.64 (m,
13H, Ar-H), 7.98 (s, 1H, OH), 8.05 (s, 1H, OH) ppm.
13C NMR (CDCl3 100 MHz): δ 36.1, 105.6, 116.4,
116.6, 124.4, 124.8, 126.4, 126.8, 128.6, 128.9, 132.8,
135.1, 145.1, 162.8 ppm. HRMS: [M + H] = m/z
413.1645; Anal. Calcd for C25H16O6: C, 72.81; H, 3.91;
found: C, 72.76; H, 3.87%.
4-Hydroxy-3-((4-hydroxy-2-oxo-2H-chromen-3-yl)(4-
nitrophenyl)methyl)-2H-chromen-2-one (3h). A light
yellow solid; 1H NMR (CDCl3 400 MHz): δ 6.10 (s, 1H,
CH), 7.24–8.09 (m, 12H, Ar-H), 8.16 (s, 1H, OH), 8.18 (s,
1H, OH) ppm. 13C NMR (CDCl3 100 MHz): δ 48.3,
116.2, 116.7, 116.8, 123.8, 124.4, 125.1, 125.2, 127.5,
133.3, 143.3, 146.9, 164.8, 169.1 ppm. HRMS:
[M + H] = m/z 458.0342; Anal. Calcd for C25H15NO8: C,
65.65; H, 3.31; N, 3.06; found: C, 65.60; H, 3.30; N, 3.29%.
4-Hydroxy-3-((4-hydroxy-2-oxo-2H-chromen-3-yl)(4-
methoxyphenyl)methyl)-2H-chromen-2-one (3i). A white
solid; 1H NMR (CDCl3 400 MHz): δ 3.78 (s, 3H,
OCH3), 6.03 (s, 1H, CH), 6.82–7.63 (m, 12H, Ar-H),
7.99 (s, 1H, OH), 8.04 (s, 1H, OH) ppm. 13C NMR
(CDCl3 100 MHz): δ 35.5, 55.2, 114.0, 116.6, 124.3,
124.8, 126.9, 127.6, 132.7, 146.9, 147.6, 152.2, 158.4,
163.9, 164.2 ppm. HRMS: [M + H] = m/z 443.1645;
Anal. Calcd for C26H18O7: C, 70.58; H, 4.10; found: C,
70.55; H, 4.07%.
3-((4-Chlorophenyl)(4-hydroxy-2-oxo-2H-chromen-3-yl)
methyl)-4-hydroxy-2H-chromen-2-one (3j). A white solid;
1H NMR (CDCl3 400 MHz): δ 6.09 (s, 1H, CH), 7.20–
7.64 (m, 12H, Ar-H), 7.98 (s, 1H, OH), 8.05 (s, 1H, OH)
ppm. 13C NMR (CDCl3 100 MHz): δ 55.2, 114.0, 116.6,
124.3, 124.8, 126.9, 127.6, 132.7, 147.0, 147.6, 152.2,
158.4, 163.9, 164.2 ppm. HRMS: [M] = m/z 460.0814.
Anal. Calcd for C25H15ClO6: C, 67.20; H, 3.38; found: C,
67.17; H, 3.87%.
3-((4-Bromophenyl)(4-hydroxy-2-oxo-2H-chromen-3-yl)
methyl)-4-hydroxy-2H-chromen-2-one (3k). A white solid;
1H NMR (CDCl3 400 MHz): δ 6.10 (s, 1H, CH), 7.24–8.09
(m, 12H, Ar-H), 8.16 (s, 1H, OH), 8.18 (s, 1H, OH) ppm.
13C NMR (CDCl3 100 MHz): δ 55.2, 114.0, 116.6, 124.3,
124.8, 126.9, 127.6, 132.7, 147.0, 147.6, 152.2, 158.4,
163.9, 164.2 ppm. HRMS: [M] = m/z 504.0209. Anal.
Calcd for C25H15BrO6: C, 61.12; H, 3.08; found: C,
61.10; H, 3.06%.
3-((4-Fluorophenyl)(4-hydroxy-2-oxo-2H-chromen-3-yl)
methyl)-4-hydroxy-2H-chromen-2-one (3l). A white solid;
1H NMR (CDCl3 400 MHz): δ 6.02 (s, 1H, CH),
6.82–7.64 (m, 12H, Ar-H), 7.99 (s, 1H, OH), 8.04 (s, 1H,
OH) ppm. 13C NMR (CDCl3 100 MHz): δ 36.1, 105.7,
116.4, 116.6, 124.4, 124.8, 126.4, 126.8, 128.6, 128.9,
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132.8, 135.1, 145.1, 162.9 ppm. HRMS: [M] = m/z
521.3130; Anal. Calcd for C25H15FO6: C, 69.77; H, 3.51;
found: C, 69.75; H, 3.50%.
3-((3-Bromo-4-methoxyphenyl)(4-hydroxy-2-oxo-2H-
chromen-3-yl)methyl)-4-hydroxy-2H-chromen-2-one (3m).
A white solid; 1H NMR (CDCl3 400 MHz): δ 3.87 (s, 3H,
OCH3), 6.02 (s, 1H, CH) 6.82–7.64 (m, 11H, Ar-H), 7.99
(s, 1H, OH), 8.05 (s, 1H, OH) ppm. 13C NMR (CDCl3
100 MHz): δ 36.1, 53.8, 105.6, 116.4, 116.6, 124.4,
124.8, 126.4, 126.8, 128.6, 128.9, 132.8, 135.1, 145.1,
162.8 ppm. HRMS: [M] = m/z 521.3130; Anal. Calcd for
C26H17BrO7: C, 59.90; H, 3.29; found: C, 59.87; H,
3.28%.
4-Hydroxy-3-((4-hydroxy-2-oxo-2H-chromen-3-yl)
(naphthalen-2-yl)methyl)-2H-chromen-2-one (3n). A white
solid; 1H NMR (CDCl3 400 MHz): δ 6.24 (s, 1H, CH),
7.24–8.00 (m, 15H, Ar-H), 8.02 (s, 1H, OH) 8.08 (s, 1H,
OH) ppm. 13C NMR (CDCl3 100 MHz): δ 36.4, 116.6,
124.4, 124.6, 124.9, 125.2, 125.8, 126.2, 127.5, 127.8,
128.4, 132.3, 132.6, 132.8, 133.3, 152.1, 152.9, 156.2,
160.9, 163.8 ppm. HRMS: [M + H] = m/z 463.6214;
Anal. Calcd for C29H18O6: C, 75.32; H, 3.92; found: C,
75.30; H, 3.89%.
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